Free Trial

Definitive Healthcare (DH) Financials

Definitive Healthcare logo
$1.25 -0.06 (-4.20%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Definitive Healthcare

Annual Income Statements for Definitive Healthcare

This table shows Definitive Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
0.00 -18 -7.22 -202 -413 -139
Consolidated Net Income / (Loss)
0.00 -62 -24 -290 -591 -199
Net Income / (Loss) Continuing Operations
-53 -62 -24 -290 -591 -199
Total Pre-Tax Income
-53 -63 -42 -308 -634 -209
Total Operating Income
-16 -27 -44 -330 -711 -224
Total Gross Profit
88 125 180 204 197 183
Total Revenue
118 166 223 251 252 242
Operating Revenue
118 166 223 251 252 242
Total Cost of Revenue
30 41 43 47 55 58
Operating Cost of Revenue
30 41 43 47 55 58
Total Operating Expenses
104 153 224 534 908 408
Selling, General & Admin Expense
14 33 52 59 49 52
Marketing Expense
34 56 90 95 84 82
Research & Development Expense
11 19 35 42 37 35
Depreciation Expense
40 39 40 39 38 36
Impairment Charge
- 0.00 0.00 287 689 196
Restructuring Charge
3.78 6.29 7.89 11 12 7.62
Total Other Income / (Expense), net
-37 -35 2.17 22 77 15
Interest Expense
36 36 11 15 15 12
Interest & Investment Income
- 0.03 2.79 14 15 6.95
Other Income / (Expense), net
-0.22 0.29 11 23 77 20
Income Tax Expense
0.00 -0.44 -18 -19 -42 -9.96
Net Income / (Loss) Attributable to Noncontrolling Interest
0.00 -44 -17 -87 -178 -60
Basic Earnings per Share
$0.00 ($0.19) ($0.07) ($1.79) ($3.54) ($1.30)
Weighted Average Basic Shares Outstanding
0.00 91.92M 101.11M 112.76M 116.64M 106.65M
Diluted Earnings per Share
$0.00 ($0.19) ($0.07) ($1.79) ($3.54) ($1.30)
Weighted Average Diluted Shares Outstanding
0.00 91.92M 101.11M 112.76M 116.64M 106.65M
Weighted Average Basic & Diluted Shares Outstanding
0.00 91.92M 107.60M 117.72M 112.91M 104.47M

Quarterly Income Statements for Definitive Healthcare

This table shows Definitive Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-9.52 -214 -131 -59 -107 -7.55 -15 -9.32 -139 -5.42 -3.89
Consolidated Net Income / (Loss)
-13 -306 -188 -85 -155 -9.27 -18 -17 -192 -7.45 -5.41
Net Income / (Loss) Continuing Operations
-13 -306 -188 -85 -155 -9.27 -18 -17 -192 -7.45 -5.41
Total Pre-Tax Income
-13 -328 -202 -91 -166 -8.81 -17 -17 -196 -7.80 -5.91
Total Operating Income
-16 -370 -225 -100 -185 -4.17 -8.69 -27 -201 -6.75 -4.97
Total Gross Profit
50 50 49 48 44 47 46 47 42 41 42
Total Revenue
63 64 63 62 59 61 60 62 56 55 55
Operating Revenue
63 64 63 62 59 61 60 62 56 55 55
Total Cost of Revenue
13 13 14 15 15 14 14 15 14 15 12
Operating Cost of Revenue
13 13 14 15 15 14 14 15 14 15 12
Total Operating Expenses
67 420 274 147 229 51 55 74 243 47 47
Selling, General & Admin Expense
17 13 11 8.50 12 13 12 14 12 11 13
Marketing Expense
22 22 20 20 21 20 20 20 20 19 19
Research & Development Expense
10 10 7.28 8.98 9.30 7.97 7.55 9.95 6.50 6.76 6.67
Depreciation Expense
9.32 9.41 9.47 9.41 8.53 9.00 9.08 9.21 8.33 8.54 8.79
Impairment Charge
0.00 364 228 - 177 0.00 0.00 20 197 0.00 0.00
Restructuring Charge
8.53 2.85 -2.00 2.84 1.27 0.67 5.31 0.38 -0.77 2.03 0.22
Total Other Income / (Expense), net
2.75 42 24 8.95 19 -4.64 -8.58 9.43 5.50 -1.05 -0.94
Interest Expense
3.82 3.76 3.75 3.51 2.94 2.99 3.00 2.87 2.63 2.63 2.66
Interest & Investment Income
3.93 3.72 3.74 3.21 2.05 1.75 1.67 1.48 1.30 1.25 1.31
Other Income / (Expense), net
2.64 42 24 9.25 20 -3.40 -7.25 11 6.83 0.33 0.41
Income Tax Expense
-0.78 -22 -14 -5.90 -11 0.46 0.52 -0.05 -3.44 -0.35 -0.50
Net Income / (Loss) Attributable to Noncontrolling Interest
-3.20 -93 -57 -26 -48 -1.71 -2.95 -7.83 -54 -2.03 -1.51
Basic Earnings per Share
($0.08) ($1.81) ($1.12) ($0.53) ($0.95) ($0.07) ($0.14) ($0.14) ($1.32) ($0.05) ($0.04)
Weighted Average Basic Shares Outstanding
117.43M 117.75M 116.38M 116.64M 112.78M 106.82M 103.78M 106.65M 104.68M 105.81M 106.77M
Diluted Earnings per Share
($0.08) ($1.81) ($1.12) ($0.53) ($0.95) ($0.07) ($0.14) ($0.14) ($1.32) ($0.05) ($0.04)
Weighted Average Diluted Shares Outstanding
117.43M 117.75M 116.38M 116.64M 112.78M 106.82M 103.78M 106.65M 104.68M 105.81M 106.77M
Weighted Average Basic & Diluted Shares Outstanding
117.93M 117.12M 115.52M 112.91M 107.34M 104.09M 103.30M 104.47M 105.52M 106.74M 107.16M

Annual Cash Flow Statements for Definitive Healthcare

This table details how cash moves in and out of Definitive Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
13 363 -240 -24 -25 57
Net Cash From Operating Activities
23 25 36 41 58 54
Net Cash From Continuing Operating Activities
21 25 35 33 58 54
Net Income / (Loss) Continuing Operations
-53 -62 -24 -290 -591 -199
Consolidated Net Income / (Loss)
-53 -62 -24 -290 -591 -199
Depreciation Expense
1.15 1.75 2.19 1.95 2.25 3.30
Amortization Expense
62 65 64 63 66 69
Non-Cash Adjustments To Reconcile Net Income
13 24 15 315 638 188
Changes in Operating Assets and Liabilities, net
-2.75 -2.95 -23 -57 -56 -6.94
Net Cash From Investing Activities
-24 -47 -249 -32 -26 154
Net Cash From Continuing Investing Activities
-24 -47 -249 -32 -26 154
Purchase of Property, Plant & Equipment
-1.40 -6.73 -8.33 -2.98 -12 -17
Acquisitions
-22 -40 -56 -45 -14 0.00
Purchase of Investments
0.00 0.00 -338 -259 -304 -64
Sale and/or Maturity of Investments
0.00 0.00 154 275 304 235
Net Cash From Financing Activities
17 384 -27 -26 -57 -151
Net Cash From Continuing Financing Activities
17 384 -27 -26 -57 -151
Repayment of Debt
-30 -478 -6.88 -8.59 -14 -254
Repurchase of Common Equity
0.00 -243 0.00 -0.03 -22 -49
Payment of Dividends
-2.94 -8.13 -13 -12 -5.14 -3.15
Issuance of Debt
25 275 - 0.00 0.00 175
Issuance of Common Equity
0.00 835 -1.73 - 0.00 0.00
Other Financing Activities, net
24 4.00 -5.22 -4.68 -15 -19
Cash Interest Paid
26 30 10 14 14 11
Cash Income Taxes Paid
0.00 0.01 0.00 0.14 0.00 0.83

Quarterly Cash Flow Statements for Definitive Healthcare

This table details how cash moves in and out of Definitive Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-25 15 16 -32 -0.10 -26 27 55 -5.53 13 6.60
Net Cash From Operating Activities
17 14 19 8.14 26 9.30 16 2.72 12 11 11
Net Cash From Continuing Operating Activities
17 14 19 8.14 26 9.50 16 2.72 12 11 11
Net Income / (Loss) Continuing Operations
-13 -306 -188 -85 -155 -9.27 -18 -17 -192 -7.45 -5.41
Consolidated Net Income / (Loss)
-13 -306 -188 -85 -155 -9.27 -18 -17 -192 -7.45 -5.41
Depreciation Expense
0.55 0.60 0.56 0.53 0.59 0.87 0.85 0.99 1.00 1.07 1.24
Amortization Expense
16 16 17 17 17 18 17 17 16 17 15
Non-Cash Adjustments To Reconcile Net Income
11 329 205 93 159 7.43 7.74 13 196 -0.40 3.05
Changes in Operating Assets and Liabilities, net
1.66 -26 -15 -17 4.01 -7.12 7.55 -11 -8.94 1.65 -2.74
Net Cash From Investing Activities
-24 15 8.96 -26 84 -10 24 56 -6.22 4.90 -2.39
Net Cash From Continuing Investing Activities
-24 15 8.96 -26 84 -10 24 56 -6.22 4.90 -2.39
Purchase of Property, Plant & Equipment
-0.27 -0.41 -0.77 -11 -7.71 -2.29 -2.28 -4.44 -3.20 -2.94 -2.39
Net Cash From Financing Activities
-17 -14 -12 -13 -110 -25 -12 -3.91 -11 -3.02 -2.44
Net Cash From Continuing Financing Activities
-17 -14 -12 -13 -110 -25 -12 -3.91 -11 -3.02 -2.44
Repayment of Debt
-3.44 -3.44 -3.44 -3.44 -248 -2.19 -2.19 -2.19 -2.19 -2.19 -2.19
Other Financing Activities, net
-14 -0.97 -0.50 -0.28 -16 -0.61 -1.06 -1.40 -8.69 -0.84 -0.25
Cash Interest Paid
3.64 3.59 3.65 -11 2.24 2.96 2.87 2.73 2.47 2.45 2.45
Cash Income Taxes Paid
0.00 - - - 0.03 - 0.18 0.63 0.09 0.11 0.13

Annual Balance Sheets for Definitive Healthcare

This table presents Definitive Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
1,745 2,118 2,123 1,826 1,089 735
Total Current Assets
64 444 414 394 370 258
Cash & Equivalents
25 387 147 131 105 164
Short-Term Investments
- 0.00 185 177 185 17
Accounts Receivable
33 43 59 59 53 52
Prepaid Expenses
3.02 6.52 13 13 13 12
Other Current Assets
2.95 6.88 10 13 14 13
Plant, Property, & Equipment, net
3.25 5.07 4.46 4.47 3.79 13
Total Noncurrent Assets
1,672 1,668 1,704 1,428 715 465
Goodwill
1,261 1,263 1,325 1,075 393 197
Intangible Assets
410 352 351 323 298 247
Other Noncurrent Operating Assets
0.47 20 29 29 24 21
Total Liabilities & Shareholders' Equity
1,745 2,118 2,123 1,826 1,089 735
Total Liabilities
550 618 641 627 482 357
Total Current Liabilities
89 123 141 171 161 157
Short-Term Debt
4.68 6.88 8.59 14 14 8.75
Accounts Payable
5.66 4.65 3.95 5.79 11 3.60
Accrued Expenses
17 28 27 52 41 45
Current Deferred Revenue
61 84 100 97 93 97
Other Current Liabilities
- 0.00 1.52 2.24 2.41 2.68
Total Noncurrent Liabilities
461 495 500 456 321 200
Long-Term Debt
457 264 256 243 229 156
Noncurrent Deferred Revenue
0.14 0.41 0.24 0.01 0.03 2.38
Noncurrent Deferred & Payable Income Tax Liabilities
0.00 229 231 194 25 34
Other Noncurrent Operating Liabilities
3.74 1.29 13 19 67 7.40
Total Equity & Noncontrolling Interests
1,196 1,500 1,482 1,199 607 379
Total Preferred & Common Equity
-0.13 871 949 861 444 281
Total Common Equity
-0.13 871 949 861 444 281
Common Stock
0.00 889 970 1,087 1,086 1,062
Retained Earnings
0.00 -18 -25 -227 -641 -780
Accumulated Other Comprehensive Income / (Loss)
-0.13 0.06 3.67 2.11 -0.61 -1.45
Noncontrolling Interest
1,196 629 533 338 163 98

Quarterly Balance Sheets for Definitive Healthcare

This table presents Definitive Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
2,105 1,820 1,810 1,422 1,182 809 770 756 515 497 489
Total Current Assets
421 375 379 368 369 273 249 246 246 240 244
Cash & Equivalents
132 77 106 121 138 106 81 108 158 171 177
Short-Term Investments
219 230 189 176 168 95 103 78 20 13 13
Accounts Receivable
45 41 57 44 36 43 38 34 39 31 30
Prepaid Expenses
14 15 13 14 14 16 14 13 16 13 13
Other Current Assets
12 12 14 14 13 14 13 13 12 12 12
Plant, Property, & Equipment, net
4.49 4.63 4.10 3.53 3.70 9.48 11 12 14 15 15
Total Noncurrent Assets
1,679 1,440 1,427 1,051 809 526 510 498 255 242 230
Goodwill
1,325 1,074 1,082 718 490 217 217 217 0.00 0.00 0.00
Intangible Assets
326 336 318 307 295 285 271 260 235 223 211
Other Noncurrent Operating Assets
29 29 27 25 24 24 22 21 20 19 18
Total Liabilities & Shareholders' Equity
2,105 1,820 1,810 1,422 1,182 809 770 756 515 497 489
Total Liabilities
649 616 615 536 486 373 359 366 324 309 300
Total Current Liabilities
148 147 165 153 148 156 151 154 140 129 124
Short-Term Debt
12 14 14 14 14 8.75 8.75 8.75 8.75 8.75 8.75
Accounts Payable
3.65 5.57 4.90 6.08 9.96 8.22 7.90 8.57 6.02 4.53 5.83
Accrued Expenses
33 36 36 34 36 27 31 42 24 24 26
Current Deferred Revenue
97 90 108 97 86 110 101 92 99 89 81
Other Current Liabilities
1.71 2.13 2.31 2.36 2.50 2.42 2.46 2.66 2.66 2.65 2.61
Total Noncurrent Liabilities
501 469 450 383 338 217 208 212 184 180 176
Long-Term Debt
249 246 239 236 233 162 160 158 154 152 150
Noncurrent Deferred Revenue
0.15 0.07 0.01 0.00 0.02 2.79 0.57 0.04 0.12 0.00 0.14
Noncurrent Deferred & Payable Income Tax Liabilities
242 204 192 128 90 37 37 15 23 23 22
Other Noncurrent Operating Liabilities
10 19 19 19 15 14 9.91 39 6.07 4.91 3.80
Total Equity & Noncontrolling Interests
1,455 1,203 1,195 886 696 436 411 390 191 188 188
Total Preferred & Common Equity
1,008 863 860 645 507 323 304 285 146 145 145
Total Common Equity
1,008 863 860 645 507 323 304 285 146 145 145
Common Stock
1,051 1,077 1,096 1,094 1,088 1,072 1,060 1,057 1,066 1,070 1,074
Retained Earnings
-46 -217 -237 -451 -581 -748 -755 -770 -918 -924 -927
Accumulated Other Comprehensive Income / (Loss)
3.25 3.05 1.66 1.06 0.34 -1.26 -1.34 -1.54 -1.56 -1.61 -1.06
Noncontrolling Interest
447 340 335 242 189 113 108 105 44 43 43

Annual Metrics And Ratios for Definitive Healthcare

This table displays calculated financial ratios and metrics derived from Definitive Healthcare's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 88,263,333.00 105,080,062.00 - - 103,303,387.00
DEI Adjusted Shares Outstanding
0.00 88,263,333.00 105,080,062.00 - - 103,303,387.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -0.20 -0.07 - - -1.34
Growth Metrics
- - - - - -
Revenue Growth
0.00% 40.43% 34.00% 12.92% 0.31% -4.24%
EBITDA Growth
0.00% -16.50% -16.38% -831.86% -134.53% 76.68%
EBIT Growth
0.00% -67.76% -23.84% -816.27% -106.61% 67.73%
NOPAT Growth
0.00% -71.96% -61.23% -648.81% -115.53% 68.45%
Net Income Growth
0.00% 0.00% 61.20% -1,097.85% -104.21% 66.30%
EPS Growth
0.00% 0.00% 63.16% -2,457.14% -97.77% 63.28%
Operating Cash Flow Growth
0.00% 8.59% 41.12% 15.77% 41.29% -7.59%
Free Cash Flow Firm Growth
0.00% 0.00% -136.90% 138.08% 148.15% -55.16%
Invested Capital Growth
0.00% -16.99% 4.75% -18.88% -51.18% -35.21%
Revenue Q/Q Growth
0.00% 0.00% 6.86% 2.17% -1.42% -0.31%
EBITDA Q/Q Growth
0.00% 0.00% 10.30% -0.47% -15.90% 36.30%
EBIT Q/Q Growth
0.00% 0.00% 12.28% -0.78% -14.09% 26.71%
NOPAT Q/Q Growth
0.00% 0.00% 8.27% 0.14% -14.40% 24.54%
Net Income Q/Q Growth
0.00% 0.00% 47.32% -7.12% -13.72% 25.32%
EPS Q/Q Growth
0.00% 0.00% 75.00% -13.29% -13.83% 23.08%
Operating Cash Flow Q/Q Growth
0.00% -15.01% -19.17% 27.68% 6.26% -9.15%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 446.53% 6.14% -30.49%
Invested Capital Q/Q Growth
0.00% 0.00% 1.48% -0.75% -12.01% -2.09%
Profitability Metrics
- - - - - -
Gross Margin
74.25% 75.51% 80.86% 81.11% 78.30% 75.88%
EBITDA Margin
39.90% 23.72% 14.80% -95.94% -224.30% -54.62%
Operating Margin
-13.43% -16.44% -19.78% -131.18% -281.85% -92.86%
EBIT Margin
-13.61% -16.26% -15.03% -121.96% -251.19% -84.64%
Profit (Net Income) Margin
0.00% -37.51% -10.86% -115.20% -234.51% -82.52%
Tax Burden Percent
0.00% 99.29% 57.74% 93.98% 93.33% 95.24%
Interest Burden Percent
326.53% 232.27% 125.14% 100.51% 100.04% 102.37%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-0.68% -1.28% -2.23% -18.02% -58.28% -34.01%
ROIC Less NNEP Spread (ROIC-NNEP)
1.90% -31.96% -8.36% 80.53% 131.75% 100.08%
Return on Net Nonoperating Assets (RNNOA)
0.68% -3.34% 0.61% -3.58% -7.21% -6.40%
Return on Equity (ROE)
0.00% -4.62% -1.62% -21.60% -65.48% -40.42%
Cash Return on Invested Capital (CROIC)
0.00% 17.28% -6.87% 2.82% 10.51% 8.71%
Operating Return on Assets (OROA)
-0.92% -1.40% -1.58% -15.53% -43.46% -22.40%
Return on Assets (ROA)
0.00% -3.23% -1.14% -14.67% -40.58% -21.84%
Return on Common Equity (ROCE)
0.00% -1.49% -0.99% -14.59% -47.34% -29.73%
Return on Equity Simple (ROE_SIMPLE)
0.00% -7.15% -2.55% -33.62% -133.10% 0.00%
Net Operating Profit after Tax (NOPAT)
-11 -19 -31 -231 -498 -157
NOPAT Margin
-9.40% -11.51% -13.85% -91.82% -197.29% -65.00%
Net Nonoperating Expense Percent (NNEP)
-2.58% 30.68% 6.13% -98.55% -190.03% -134.10%
Return On Investment Capital (ROIC_SIMPLE)
- - -1.77% -15.86% -58.52% -28.87%
Cost of Revenue to Revenue
25.75% 24.49% 19.14% 18.89% 21.70% 24.12%
SG&A Expenses to Revenue
12.14% 19.78% 23.16% 23.41% 19.53% 21.38%
R&D to Revenue
9.35% 11.17% 15.67% 16.88% 14.48% 14.40%
Operating Expenses to Revenue
87.68% 91.95% 100.64% 212.29% 360.14% 168.74%
Earnings before Interest and Taxes (EBIT)
-16 -27 -33 -307 -634 -204
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
47 39 33 -241 -566 -132
Valuation Ratios
- - - - - -
Price to Book Value (P/BV)
0.00 2.77 1.22 1.34 1.07 1.05
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
3.55 14.52 5.19 4.60 1.88 1.23
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.26 2.14 1.15 1.26 1.05 1.04
Enterprise Value to Revenue (EV/Rev)
17.35 17.40 7.28 5.74 2.34 1.57
Enterprise Value to EBITDA (EV/EBITDA)
43.49 73.35 49.16 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
88.42 114.68 45.54 35.02 10.15 7.03
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 11.24 0.00 39.90 6.58 9.41
Leverage & Solvency
- - - - - -
Debt to Equity
0.39 0.18 0.18 0.21 0.40 0.43
Long-Term Debt to Equity
0.38 0.18 0.17 0.20 0.38 0.41
Financial Leverage
0.36 0.10 -0.07 -0.04 -0.05 -0.06
Leverage Ratio
1.46 1.43 1.42 1.47 1.61 1.85
Compound Leverage Factor
4.77 3.33 1.78 1.48 1.61 1.89
Debt to Total Capital
27.87% 15.29% 15.14% 17.61% 28.59% 30.31%
Short-Term Debt to Total Capital
0.28% 0.39% 0.49% 0.94% 1.62% 1.61%
Long-Term Debt to Total Capital
27.58% 14.90% 14.65% 16.67% 26.97% 28.70%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
72.14% 35.50% 30.52% 23.21% 19.15% 18.00%
Common Equity to Total Capital
-0.01% 49.21% 54.34% 59.18% 52.26% 51.69%
Debt to EBITDA
9.78 6.87 8.02 -1.06 -0.43 -1.25
Net Debt to EBITDA
9.26 -3.79 -2.05 0.21 0.08 0.12
Long-Term Debt to EBITDA
9.69 6.69 7.76 -1.01 -0.41 -1.18
Debt to NOPAT
-41.54 -14.16 -8.57 -1.11 -0.49 -1.05
Net Debt to NOPAT
-39.31 7.82 2.19 0.22 0.09 0.10
Long-Term Debt to NOPAT
-41.11 -13.80 -8.30 -1.05 -0.46 -0.99
Altman Z-Score
0.48 2.55 1.27 0.66 -1.69 -1.41
Noncontrolling Interest Sharing Ratio
100.01% 67.68% 38.96% 32.48% 27.72% 26.44%
Liquidity Ratios
- - - - - -
Current Ratio
0.72 3.61 2.94 2.31 2.30 1.64
Quick Ratio
0.65 3.50 2.78 2.15 2.13 1.49
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 257 -95 36 90 40
Operating Cash Flow to CapEx
1,664.30% 374.57% 427.32% 1,383.61% 471.45% 321.63%
Free Cash Flow to Firm to Interest Expense
0.00 7.19 -8.47 2.38 6.05 3.41
Operating Cash Flow to Interest Expense
0.64 0.70 3.18 2.71 3.92 4.56
Operating Cash Flow Less CapEx to Interest Expense
0.60 0.52 2.43 2.51 3.09 3.14
Efficiency Ratios
- - - - - -
Asset Turnover
0.07 0.09 0.11 0.13 0.17 0.26
Accounts Receivable Turnover
3.57 4.35 4.36 4.26 4.48 4.59
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
36.43 39.96 46.71 56.28 61.05 29.33
Accounts Payable Turnover
5.38 7.89 9.91 9.75 6.61 8.11
Days Sales Outstanding (DSO)
102.14 83.96 83.72 85.69 81.39 79.50
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
67.83 46.26 36.82 37.42 55.18 44.99
Cash Conversion Cycle (CCC)
34.31 37.71 46.90 48.27 26.21 34.51
Capital & Investment Metrics
- - - - - -
Invested Capital
1,627 1,350 1,414 1,147 560 363
Invested Capital Turnover
0.07 0.11 0.16 0.20 0.30 0.52
Increase / (Decrease) in Invested Capital
0.00 -276 64 -267 -587 -197
Enterprise Value (EV)
2,053 2,891 1,620 1,442 591 378
Market Capitalization
420 2,412 1,155 1,156 475 296
Book Value per Share
($0.01) $9.87 $9.03 $7.40 $3.85 $2.72
Tangible Book Value per Share
($107.47) ($8.43) ($6.91) ($4.61) ($2.14) ($1.58)
Total Capital
1,657 1,771 1,746 1,455 850 544
Total Debt
462 271 264 256 243 165
Total Long-Term Debt
457 264 256 243 229 156
Net Debt
437 -149 -68 -52 -47 -16
Capital Expenditures (CapEx)
1.40 6.73 8.33 2.98 12 17
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-45 -60 -50 -71 -67 -71
Debt-free Net Working Capital (DFNWC)
-20 328 282 237 223 110
Net Working Capital (NWC)
-25 321 273 223 209 101
Net Nonoperating Expense (NNE)
-11 43 -6.65 59 94 42
Net Nonoperating Obligations (NNO)
431 -149 -68 -52 -47 -16
Total Depreciation and Amortization (D&A)
63 66 66 65 68 73
Debt-free, Cash-free Net Working Capital to Revenue
-38.01% -35.82% -22.52% -28.27% -26.73% -29.53%
Debt-free Net Working Capital to Revenue
-17.07% 197.40% 126.53% 94.26% 88.33% 45.37%
Net Working Capital to Revenue
-21.03% 193.26% 122.67% 88.80% 82.87% 41.74%
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 ($0.19) ($0.06) ($1.79) ($3.54) ($1.30)
Adjusted Weighted Average Basic Shares Outstanding
0.00 97.39M 101.11M 112.76M 116.64M 106.65M
Adjusted Diluted Earnings per Share
$0.00 ($0.19) ($0.06) ($1.79) ($3.54) ($1.30)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 97.39M 101.11M 112.76M 116.64M 106.65M
Adjusted Basic & Diluted Earnings per Share
$0.00 ($0.19) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 91.92M 107.60M 117.72M 112.91M 104.47M
Normalized Net Operating Profit after Tax (NOPAT)
-8.48 -15 -25 -22 -6.82 -14
Normalized NOPAT Margin
-7.16% -8.86% -11.37% -8.61% -2.70% -5.97%
Pre Tax Income Margin
-44.46% -37.78% -18.81% -122.58% -251.28% -86.64%
Debt Service Ratios
- - - - - -
EBIT to Interest Expense
-0.44 -0.76 -2.99 -20.17 -42.70 -17.33
NOPAT to Interest Expense
-0.30 -0.53 -2.75 -15.19 -33.54 -13.31
EBIT Less CapEx to Interest Expense
-0.48 -0.94 -3.73 -20.36 -43.53 -18.75
NOPAT Less CapEx to Interest Expense
-0.34 -0.72 -3.50 -15.38 -34.37 -14.73
Payout Ratios
- - - - - -
Dividend Payout Ratio
0.00% -13.04% -53.23% -4.24% -0.87% -1.58%
Augmented Payout Ratio
0.00% -403.71% -53.23% -4.25% -4.65% -26.39%

Quarterly Metrics And Ratios for Definitive Healthcare

This table displays calculated financial ratios and metrics derived from Definitive Healthcare's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - 112,911,325.00 107,341,903.00 104,086,210.00 103,303,387.00 104,472,371.00 105,524,238.00 106,744,713.00
DEI Adjusted Shares Outstanding
- - - - 112,911,325.00 107,341,903.00 104,086,210.00 103,303,387.00 104,472,371.00 105,524,238.00 106,744,713.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - -0.95 -0.07 -0.14 -0.09 -1.33 -0.05 -0.04
Growth Metrics
- - - - - - - - - - -
Revenue Growth
7.23% 4.56% -4.02% -5.53% -6.76% -4.69% -4.23% -1.21% -5.51% -9.14% -8.99%
EBITDA Growth
3,673.08% -9,662.21% 26.00% -1,686.79% -5,101.73% 103.50% 101.22% 102.96% -20.45% 3.26% 431.38%
EBIT Growth
14.42% -2,449.28% 24.17% -648.71% -1,113.10% 97.69% 92.09% 82.49% -17.79% 15.14% 71.41%
NOPAT Growth
-32.42% -2,962.22% 23.70% -887.73% -1,037.21% 98.87% 96.15% 73.26% -8.93% -61.82% 42.84%
Net Income Growth
20.37% -2,538.41% 24.47% -534.01% -1,119.48% 96.97% 90.53% 79.76% -24.02% 19.57% 69.62%
EPS Growth
27.27% -2,162.50% 25.33% -430.00% -1,087.50% 96.13% 87.50% 73.58% -38.95% 28.57% 71.43%
Operating Cash Flow Growth
10.91% 16.64% 104.83% 72.75% 57.13% -33.73% -19.27% -66.56% -55.64% 23.13% -27.19%
Free Cash Flow Firm Growth
502.93% 65.73% 1,065.65% 99.11% 182.50% 64.67% -28.16% -65.50% -85.40% -48.60% -19.10%
Invested Capital Growth
-16.62% -38.53% -44.93% -51.18% -64.75% -52.82% -41.77% -35.21% -56.85% -58.36% -57.64%
Revenue Q/Q Growth
-3.72% 0.40% -1.63% -0.65% -4.97% 2.63% -1.16% 2.48% -9.11% -1.31% -0.99%
EBITDA Q/Q Growth
-36.05% -10,675.94% 40.77% 60.39% -101.58% 107.39% -79.32% -4.09% -8,316.36% 106.34% 6.41%
EBIT Q/Q Growth
-12.83% -2,310.47% 38.56% 55.19% -82.81% 95.42% -110.58% 0.76% -1,129.50% 96.70% 29.06%
NOPAT Q/Q Growth
-61.20% -2,174.85% 39.03% 55.82% -85.60% 97.74% -108.35% -206.48% -655.96% 96.65% 26.41%
Net Income Q/Q Growth
4.82% -2,307.51% 38.66% 54.90% -83.07% 94.03% -92.03% 3.63% -1,021.79% 96.13% 27.46%
EPS Q/Q Growth
20.00% -2,162.50% 38.12% 52.68% -79.25% 92.63% -100.00% 0.00% -842.86% 96.21% 20.00%
Operating Cash Flow Q/Q Growth
252.28% -15.37% 38.40% -58.14% 220.42% -64.31% 68.60% -82.66% 325.15% -0.93% -0.30%
Free Cash Flow Firm Q/Q Growth
-15.96% 22.45% 35.21% 43.10% 19.24% -28.62% -41.02% -31.27% -49.53% 151.25% -7.17%
Invested Capital Q/Q Growth
0.48% -27.18% -24.17% -12.01% -27.45% -2.53% -6.41% -2.09% -51.69% -5.95% -4.79%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
79.37% 79.16% 78.20% 76.42% 73.93% 76.73% 76.60% 76.23% 74.47% 73.45% 77.27%
EBITDA Margin
4.64% -488.33% -294.05% -117.24% -248.69% 17.91% 3.75% 3.51% -317.03% 20.36% 21.88%
Operating Margin
-25.60% -579.95% -359.45% -159.84% -312.19% -6.86% -14.47% -43.27% -359.90% -12.23% -9.09%
EBIT Margin
-21.44% -514.68% -321.45% -144.99% -278.91% -12.46% -26.54% -25.70% -347.69% -11.64% -8.34%
Profit (Net Income) Margin
-20.03% -480.39% -299.57% -136.01% -262.02% -15.25% -29.63% -27.87% -343.93% -13.50% -9.89%
Tax Burden Percent
94.22% 93.32% 93.19% 93.49% 93.44% 105.18% 103.03% 99.69% 98.25% 95.58% 91.50%
Interest Burden Percent
99.18% 100.01% 100.00% 100.34% 100.54% 116.40% 108.35% 108.75% 100.69% 121.41% 129.68%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-3.61% -95.16% -71.82% -33.05% -69.49% -1.91% -4.87% -15.85% -206.38% -7.10% -5.48%
ROIC Less NNEP Spread (ROIC-NNEP)
-1.43% -25.66% -15.29% -2.64% 2.33% 18.58% 25.17% -20.58% 22.81% 7.21% 2.17%
Return on Net Nonoperating Assets (RNNOA)
0.07% 1.50% 0.86% 0.14% -0.10% -0.89% -1.81% 1.32% -1.63% -0.46% -0.19%
Return on Equity (ROE)
-3.55% -93.67% -70.97% -32.91% -69.59% -2.79% -6.68% -14.53% -208.01% -7.56% -5.67%
Cash Return on Invested Capital (CROIC)
-0.30% 3.84% 9.43% 10.51% 16.80% 13.55% 11.49% 8.71% 21.48% 21.68% 17.41%
Operating Return on Assets (OROA)
-2.79% -75.43% -54.81% -25.09% -52.81% -2.78% -6.64% -6.80% -125.19% -4.27% -3.05%
Return on Assets (ROA)
-2.61% -70.40% -51.08% -23.53% -49.61% -3.41% -7.41% -7.38% -123.84% -4.96% -3.61%
Return on Common Equity (ROCE)
-2.46% -66.13% -51.19% -23.79% -50.48% -2.04% -4.87% -10.69% -155.69% -5.66% -4.22%
Return on Equity Simple (ROE_SIMPLE)
-33.29% -90.10% -102.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-11 -259 -158 -70 -129 -2.92 -6.08 -19 -141 -4.72 -3.48
NOPAT Margin
-17.92% -405.96% -251.62% -111.89% -218.53% -4.80% -10.13% -30.29% -251.93% -8.56% -6.36%
Net Nonoperating Expense Percent (NNEP)
-2.18% -69.51% -56.53% -30.41% -71.82% -20.48% -30.04% 4.73% -229.19% -14.31% -7.65%
Return On Investment Capital (ROIC_SIMPLE)
- - - -8.20% -21.31% -0.50% -1.09% -3.43% -39.87% -1.36% -1.00%
Cost of Revenue to Revenue
20.63% 20.84% 21.80% 23.58% 26.07% 23.27% 23.40% 23.77% 25.53% 26.55% 22.73%
SG&A Expenses to Revenue
26.60% 19.65% 18.11% 13.65% 20.73% 20.86% 20.59% 23.27% 21.61% 19.58% 23.41%
R&D to Revenue
15.96% 15.88% 11.61% 14.42% 15.71% 13.12% 12.58% 16.18% 11.62% 12.24% 12.20%
Operating Expenses to Revenue
104.96% 659.11% 437.66% 236.27% 386.12% 83.59% 91.07% 119.50% 434.37% 85.68% 86.36%
Earnings before Interest and Taxes (EBIT)
-14 -328 -202 -90 -165 -7.57 -16 -16 -194 -6.42 -4.56
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
2.94 -311 -184 -73 -147 11 2.25 2.16 -177 11 12
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.10 1.00 1.03 1.07 1.01 1.38 1.48 1.05 0.88 0.61 0.66
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
3.72 2.49 2.05 1.88 1.32 1.71 1.74 1.23 0.54 0.38 0.43
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.08 1.00 1.03 1.05 1.01 1.29 1.37 1.04 0.90 0.65 0.69
Enterprise Value to Revenue (EV/Rev)
4.86 3.24 2.55 2.34 1.65 2.09 2.10 1.57 0.66 0.46 0.48
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
29.02 18.71 11.93 10.15 6.06 8.12 8.59 7.03 4.01 2.61 2.91
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 19.82 7.73 6.58 3.13 6.11 8.79 9.41 2.52 1.77 2.36
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.21 0.28 0.35 0.40 0.39 0.41 0.43 0.43 0.85 0.86 0.84
Long-Term Debt to Equity
0.20 0.27 0.33 0.38 0.37 0.39 0.41 0.41 0.81 0.81 0.79
Financial Leverage
-0.05 -0.06 -0.06 -0.05 -0.04 -0.05 -0.07 -0.06 -0.07 -0.06 -0.09
Leverage Ratio
1.48 1.51 1.58 1.61 1.61 1.69 1.79 1.85 2.11 2.11 2.15
Compound Leverage Factor
1.46 1.51 1.58 1.62 1.61 1.97 1.93 2.01 2.13 2.57 2.79
Debt to Total Capital
17.47% 21.98% 26.16% 28.59% 28.19% 29.13% 29.99% 30.31% 46.04% 46.09% 45.69%
Short-Term Debt to Total Capital
0.95% 1.21% 1.46% 1.62% 1.44% 1.51% 1.57% 1.61% 2.48% 2.51% 2.52%
Long-Term Debt to Total Capital
16.52% 20.77% 24.70% 26.97% 26.75% 27.62% 28.42% 28.70% 43.57% 43.58% 43.17%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
23.12% 21.26% 20.07% 19.15% 18.64% 18.55% 18.83% 18.00% 12.58% 12.40% 12.43%
Common Equity to Total Capital
59.41% 56.76% 53.77% 52.26% 53.17% 52.32% 51.18% 51.69% 41.38% 41.51% 41.88%
Debt to EBITDA
-1.06 -0.45 -0.50 -0.43 -0.24 -0.43 -0.81 -1.25 -1.00 -0.99 -1.04
Net Debt to EBITDA
0.18 0.08 0.12 0.08 0.04 0.04 0.09 0.12 0.09 0.14 0.21
Long-Term Debt to EBITDA
-1.00 -0.43 -0.48 -0.41 -0.23 -0.41 -0.76 -1.18 -0.95 -0.94 -0.99
Debt to NOPAT
-1.08 -0.52 -0.57 -0.49 -0.28 -0.47 -0.80 -1.05 -0.97 -0.94 -0.95
Net Debt to NOPAT
0.18 0.10 0.14 0.09 0.05 0.04 0.09 0.10 0.09 0.13 0.19
Long-Term Debt to NOPAT
-1.02 -0.49 -0.53 -0.46 -0.26 -0.45 -0.76 -0.99 -0.91 -0.89 -0.89
Altman Z-Score
1.00 -0.12 -0.17 -0.04 -0.96 -0.24 -0.34 -0.56 -2.80 -1.74 -1.74
Noncontrolling Interest Sharing Ratio
30.62% 29.40% 27.87% 27.72% 27.46% 26.91% 27.08% 26.44% 25.15% 25.18% 25.59%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.30 2.40 2.49 2.30 1.75 1.65 1.60 1.64 1.75 1.86 1.96
Quick Ratio
2.13 2.22 2.30 2.13 1.56 1.47 1.43 1.49 1.55 1.66 1.77
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
218 268 362 518 617 441 260 179 90 226 210
Operating Cash Flow to CapEx
6,236.47% 3,424.39% 2,533.51% 74.63% 338.26% 405.76% 687.72% 61.26% 361.15% 389.40% 478.71%
Free Cash Flow to Firm to Interest Expense
57.25 71.09 96.48 147.50 209.92 147.33 86.64 62.31 34.28 86.16 79.02
Operating Cash Flow to Interest Expense
4.35 3.73 5.18 2.32 8.87 3.11 5.23 0.95 4.40 4.36 4.29
Operating Cash Flow Less CapEx to Interest Expense
4.28 3.62 4.98 -0.79 6.24 2.34 4.47 -0.60 3.18 3.24 3.40
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.13 0.15 0.17 0.17 0.19 0.22 0.25 0.26 0.36 0.37 0.37
Accounts Receivable Turnover
4.72 5.83 6.64 4.48 4.98 6.00 6.91 4.59 5.82 6.80 7.12
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
59.80 64.51 61.41 61.05 36.50 34.89 31.54 29.33 20.47 18.42 16.96
Accounts Payable Turnover
10.32 10.44 6.77 6.61 8.70 8.29 6.29 8.11 8.02 9.27 7.78
Days Sales Outstanding (DSO)
77.41 62.63 54.97 81.39 73.30 60.87 52.82 79.50 62.71 53.70 51.29
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
35.36 34.96 53.92 55.18 41.94 44.04 58.01 44.99 45.52 39.37 46.94
Cash Conversion Cycle (CCC)
42.05 27.67 1.05 26.21 31.37 16.83 -5.18 34.51 17.18 14.33 4.35
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
1,153 839 637 560 406 396 371 363 175 165 157
Invested Capital Turnover
0.20 0.23 0.29 0.30 0.32 0.40 0.48 0.52 0.82 0.83 0.86
Increase / (Decrease) in Invested Capital
-230 -526 -519 -587 -747 -443 -266 -197 -231 -231 -214
Enterprise Value (EV)
1,243 839 654 591 410 511 508 378 158 108 108
Market Capitalization
950 644 524 475 326 419 423 296 129 88 97
Book Value per Share
$7.31 $5.47 $4.32 $3.85 $2.86 $2.83 $2.74 $2.72 $1.40 $1.37 $1.36
Tangible Book Value per Share
($4.59) ($3.23) ($2.38) ($2.14) ($1.58) ($1.72) ($1.84) ($1.58) ($0.85) ($0.74) ($0.62)
Total Capital
1,448 1,136 942 850 607 580 557 544 353 349 347
Total Debt
253 250 246 243 171 169 167 165 163 161 159
Total Long-Term Debt
239 236 233 229 162 160 158 156 154 152 150
Net Debt
-42 -47 -59 -47 -30 -15 -19 -16 -15 -23 -31
Capital Expenditures (CapEx)
0.27 0.41 0.77 11 7.71 2.29 2.28 4.44 3.20 2.94 2.39
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-68 -68 -71 -67 -75 -78 -85 -71 -64 -64 -62
Debt-free Net Working Capital (DFNWC)
227 229 234 223 126 107 101 110 114 120 128
Net Working Capital (NWC)
214 215 221 209 117 98 92 101 105 111 120
Net Nonoperating Expense (NNE)
1.34 47 30 15 26 6.35 12 -1.49 51 2.73 1.93
Net Nonoperating Obligations (NNO)
-42 -47 -59 -47 -30 -15 -19 -16 -15 -23 -31
Total Depreciation and Amortization (D&A)
17 17 17 17 18 18 18 18 17 18 17
Debt-free, Cash-free Net Working Capital to Revenue
-26.47% -26.28% -27.80% -26.73% -30.07% -31.65% -34.98% -29.53% -26.86% -27.42% -27.13%
Debt-free Net Working Capital to Revenue
88.97% 88.44% 91.56% 88.33% 50.87% 43.56% 41.76% 45.37% 47.89% 51.47% 56.45%
Net Working Capital to Revenue
83.59% 83.12% 86.19% 82.87% 47.34% 39.99% 38.15% 41.74% 44.22% 47.71% 52.60%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.08) ($1.81) ($1.12) ($0.53) ($0.95) ($0.07) ($0.14) ($0.14) ($1.32) ($0.05) ($0.04)
Adjusted Weighted Average Basic Shares Outstanding
117.43M 117.75M 116.38M 116.64M 112.78M 106.82M 103.78M 106.65M 104.68M 105.81M 106.77M
Adjusted Diluted Earnings per Share
($0.08) ($1.81) ($1.12) ($0.53) ($0.95) ($0.07) ($0.14) ($0.14) ($1.32) ($0.05) ($0.04)
Adjusted Weighted Average Diluted Shares Outstanding
117.43M 117.75M 116.38M 116.64M 112.78M 106.82M 103.78M 106.65M 104.68M 105.81M 106.77M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
117.93M 117.12M 115.52M 112.91M 107.34M 104.09M 103.30M 104.47M 105.52M 106.74M 107.16M
Normalized Net Operating Profit after Tax (NOPAT)
-5.40 -2.20 0.55 -68 -4.89 -2.45 -2.37 -4.70 -3.39 -3.30 -3.32
Normalized NOPAT Margin
-8.51% -3.46% 0.88% -108.70% -8.27% -4.03% -3.94% -7.64% -6.05% -5.99% -6.08%
Pre Tax Income Margin
-21.26% -514.75% -321.46% -145.47% -280.41% -14.50% -28.76% -27.95% -350.07% -14.13% -10.81%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-3.57 -87.18 -53.76 -25.74 -56.15 -2.53 -5.31 -5.52 -73.97 -2.44 -1.71
NOPAT to Interest Expense
-2.98 -68.76 -42.08 -19.86 -44.00 -0.98 -2.03 -6.50 -53.60 -1.80 -1.31
EBIT Less CapEx to Interest Expense
-3.64 -87.28 -53.96 -28.84 -58.77 -3.30 -6.07 -7.07 -75.18 -3.56 -2.61
NOPAT Less CapEx to Interest Expense
-3.05 -68.87 -42.28 -22.97 -46.62 -1.74 -2.79 -8.05 -54.81 -2.92 -2.20
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% -2.09% -0.85% -0.87% 0.00% -1.20% -1.93% -1.58% 0.00% -0.14% -0.14%
Augmented Payout Ratio
0.00% -3.31% -3.74% -4.65% -5.93% -13.93% -23.21% -26.39% -11.96% -4.06% -0.14%

Financials Breakdown Chart

Key Financial Trends

Definitive Healthcare Corp. (NASDAQ:DH) continues to generate positive operating cash flow, but its latest results show weak top-line momentum and ongoing GAAP losses. The company’s Q2 2026 revenue was $55.2 million, down from $55.9 million in Q1 2026 and approximately 9% from $60.8 million in Q2 2025. This extends a broader revenue decline from the roughly $63 million to $66 million quarterly range reported through much of 2023 and early 2024.

Profitability improved substantially from Q1 2026, primarily because the company recorded no impairment charge in Q2. Q1 included a $197.2 million impairment charge, while Q4 2025 included a $19.5 million charge and earlier 2024 quarters included much larger impairment expenses. Even without an impairment charge, however, Definitive Healthcare posted a $6.7 million operating loss and a $7.5 million consolidated net loss in Q2. Gross margin also fell to approximately 73.5%, compared with 76.8% in Q2 2025.

  • Operating cash flow remains positive. Q2 2026 operating cash flow was $11.5 million, broadly in line with $11.6 million in Q1 and above the $9.3 million reported in Q2 2025. The company has generated positive operating cash flow in each supplied quarter despite recurring GAAP losses.
  • Cash liquidity improved during the quarter. Cash and equivalents rose to $170.9 million from $157.6 million at Q1-end. Including short-term investments, liquid resources totaled approximately $183.6 million, providing a meaningful buffer against ongoing operating losses and debt obligations.
  • Debt balances are gradually declining. Total short- and long-term debt was approximately $160.6 million at June 30, 2026, down from $162.7 million at March 31 and $169.0 million a year earlier. Q2 financing activities included $2.2 million of debt repayment.
  • Large impairment charges have subsided in the latest quarter. Definitive Healthcare reported no impairment charge in Q2 2026, a significant improvement from the $197.2 million charge in Q1 2026 and the $363.6 million charge in Q2 2024. This helped narrow the operating and net losses on a sequential basis.
  • Cash generation depends heavily on noncash adjustments. Q2 operating cash flow was supported by $16.6 million of amortization and other noncash adjustments, while consolidated net income was negative $7.5 million. This is not necessarily a liquidity problem, but investors should distinguish cash-flow strength from sustainable GAAP profitability.
  • Investment activity has been an important source of cash volatility. Q2 investing cash flow was positive $4.9 million because $7.8 million of investments matured or were sold, partially offset by $2.9 million of capital spending. Similar investment purchases and sales caused large swings in cash flow during 2023 through 2025.
  • Revenue growth remains the primary concern. Q2 2026 revenue declined both sequentially and year over year, while revenue has generally trended below the 2023-2024 levels. Continued contraction could make it more difficult for the company to absorb its substantial marketing, research and development, depreciation and amortization costs.
  • The company remains unprofitable at the operating and net-income levels. Q2 operating expenses totaled $47.3 million against $40.5 million of gross profit, producing a $6.7 million operating loss. Net loss attributable to common shareholders was $5.4 million, or $0.05 per diluted share.
  • Interest expense continues to pressure results. Q2 interest expense was $2.6 million, compared with $1.3 million of interest and investment income. The company also paid $2.4 million of cash interest during the quarter, limiting the benefit of positive operating cash flow.
  • The balance sheet remains exposed to intangible-asset and restructuring risk. Intangible assets were $222.7 million, or roughly 45% of total assets, while retained earnings remained negative at $923.5 million. Definitive Healthcare also recorded a $2.0 million restructuring charge in Q2, indicating that cost reductions and business realignment remain ongoing.

Overall, Q2 2026 showed better cash generation and a sharp reduction in reported losses after the Q1 impairment, but the improvement was not driven by revenue growth or a return to operating profitability. The key issues for investors are whether management can stabilize declining revenue, reduce recurring expenses and convert positive cash flow into durable earnings without relying on investment maturities or noncash adjustments.

11/16/26 04:01 PM ETAI Generated. May Contain Errors.

Definitive Healthcare Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Definitive Healthcare's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Definitive Healthcare's net income appears to be on a downward trend, with a most recent value of -$199.30 million in 2025, compared with $0.00 in 2020. The previous period was -$591.45 million in 2024. Check out Definitive Healthcare's forecast to explore projected trends and price targets.

Definitive Healthcare's total operating income in 2025 was -$224.27 million, based on the following breakdown:
  • Total Gross Profit: $183.28 million
  • Total Operating Expenses: $407.55 million

Over the last 5 years, Definitive Healthcare's total revenue changed from $118.32 million in 2020 to $241.52 million in 2025, a change of 104.1%.

In the past 13 quarters, Definitive Healthcare's cash and equivalents has ranged from $77.46 million in Q3 2023 to $177.14 million in Q3 2026, and is currently $177.14 million as of their latest financial filing in Q3 2026.

Definitive Healthcare had total debt of $164.84 million at the end of 2025, a 32.2% decrease from 2024, and a 64.3% decrease since 2020.

Over the last 5 years, Definitive Healthcare's book value per share changed from -0.01 in 2020 to 2.72 in 2025.



Financial statements for NASDAQ:DH last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners